NovaBay Pharmaceuticals (NBY) Retained Earnings (2016 - 2025)
Historic Retained Earnings for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$183.8 million.
- NovaBay Pharmaceuticals' Retained Earnings fell 86.26% to -$183.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.8 million, marking a year-over-year decrease of 86.26%. This contributed to the annual value of -$183.5 million for FY2024, which is 492.31% down from last year.
- Latest data reveals that NovaBay Pharmaceuticals reported Retained Earnings of -$183.8 million as of Q3 2025, which was down 86.26% from -$177.7 million recorded in Q2 2025.
- In the past 5 years, NovaBay Pharmaceuticals' Retained Earnings ranged from a high of -$137.6 million in Q1 2021 and a low of -$183.8 million during Q3 2025
- Moreover, its 5-year median value for Retained Earnings was -$163.9 million (2023), whereas its average is -$162.1 million.
- Its Retained Earnings has fluctuated over the past 5 years, first crashed by 1371.46% in 2023, then surged by 148.84% in 2025.
- NovaBay Pharmaceuticals' Retained Earnings (Quarter) stood at -$141.9 million in 2021, then fell by 11.46% to -$158.2 million in 2022, then fell by 10.56% to -$174.8 million in 2023, then decreased by 4.92% to -$183.5 million in 2024, then dropped by 0.2% to -$183.8 million in 2025.
- Its Retained Earnings was -$183.8 million in Q3 2025, compared to -$177.7 million in Q2 2025 and -$175.8 million in Q1 2025.